Clinical Trials

39 enrolled

Endometrioid Endometrial Cancer

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT06869226 2025-10-02

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

283 enrolled

Esophageal Neoplasms

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

39 enrolled

Salivary Gland Neoplasms

NCT07100392 2025-08-17

LEAF-02

141 enrolled

Carcinoma, Hepatocellular

NCT07105748 2025-08-17

TASK-05

45 enrolled

Liver Neoplasms

NCT07057089 2025-08-14

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)

90 enrolled

Locally Advanced Rectal Cancer

NCT06831175 2025-06-03

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

28 enrolled

Endocrine

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

NCT06288360 2025-03-20

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

40 enrolled

Uterine Cervical Neoplasms

NCT05512481 2025-03-03

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

60 enrolled

Dermatologic

Melanoma

NCT04299581 2025-02-27

Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma

25 enrolled

Cholangiocarcinoma

NCT05475678 2025-01-23

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

369 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06516289 2024-12-12

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

130 enrolled

BRCA-Mutated Breast Carcinoma

NCT06711471 2024-12-02

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

31 enrolled

Gastric Cancer Adenocarcinoma Metastatic

NCT06289062 2024-11-05

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

40 enrolled

Uterine Cervical Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

620 enrolled

Breast Neoplasms

NCT05412589 2024-07-31

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

35 enrolled

Liver Neoplasms

NCT06516445 2024-07-24

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

33 enrolled

Colorectal Neoplasms

NCT06423170 2024-05-21

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

GastrointestinalGenitourinary

37 enrolled

Unresectable Gallbladder Cancer

NCT06413992 2024-05-14

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

117 enrolled

Neoplasm Metastasis, Recurrence, Endometrial Neoplasms

NCT06148402 2024-05-13

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

30 enrolled

Colorectal Neoplasms

NCT06363825 2024-04-17

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

57 enrolled

Carcinoma, Hepatocellular

NCT04830267 2024-03-28

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

39 enrolled

Nasopharyngeal Carcinoma

NCT05011227 2024-03-06

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

100 enrolled

Nasopharyngeal Carcinoma

NCT06241807 2024-02-14

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06176885 2023-12-27

FOBECAMS

36 enrolled

Colorectal Neoplasms

NCT05069857 2023-11-22

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

46 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05749588 2023-11-14

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

120 enrolled

Triple Negative Breast Neoplasms

NCT06074692 2023-10-31

PRIMA

86 enrolled

Sarcoma

Sarcoma, Osteosarcoma

NCT05624099 2023-10-19

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

75 enrolled

Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms

NCT05841472 2023-08-30

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

60 enrolled

Non Squamous Non Small Cell Lung Cancer

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

35 enrolled

Triple Negative Breast Neoplasms

NCT05213884 2023-05-06

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05825443 2023-04-25

PANORAMA

57 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05761470 2023-03-09

IMPARP

66 enrolled

Her-2 Negative Breast Cancer

NCT04812002 2022-06-03

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

20 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Gestational Trophoblastic Disease

NCT05311566 2022-04-13

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

92 enrolled

Uterine Cervical Neoplasms

NCT05053802 2021-09-23

MAGIC

146 enrolled

Multiple Primary Lung Cancer

NCT04826679 2021-04-01

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

53 enrolled